Your browser doesn't support javascript.
loading
The Full Value of Vaccine Assessments Concept-Current Opportunities and Recommendations.
White, Richard G; Menzies, Nicolas A; Portnoy, Allison; Clark, Rebecca A; Toscano, Cristiana M; Weller, Charlotte; Tufet Bayona, Marta; Silal, Sheetal Prakash; Karron, Ruth A; Lee, Jung-Seok; Excler, Jean-Louis; Lauer, Jeremy A; Giersing, Birgitte; Lambach, Philipp; Hutubessy, Raymond; Jit, Mark.
Afiliación
  • White RG; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Menzies NA; Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Portnoy A; Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Clark RA; Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Toscano CM; Department of Global Health, Boston University School of Public Health, Boston, MA 02118, USA.
  • Weller C; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Tufet Bayona M; Department of Collective Health, Institute for Tropical Medicine and Public Health, Federal University of Goiás (UFG), Goiânia 74690-900, Brazil.
  • Silal SP; Wellcome, London NW1 2BE, UK.
  • Karron RA; Gavi, 1218 Geneva, Switzerland.
  • Lee JS; Modelling and Simulation Hub, Africa, Department of Statistical Sciences, University of Cape Town, Cape Town 7701, South Africa.
  • Excler JL; Centre for Global Health, Nuffield Department of Medicine, Oxford University, Oxford OX3 7BN, UK.
  • Lauer JA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
  • Giersing B; Policy and Economic Research Department, International Vaccine Institute, Seoul 08826, Republic of Korea.
  • Lambach P; International Vaccine Institute, Seoul 08826, Republic of Korea.
  • Hutubessy R; Department of Management Science, Strathclyde Business School, Strathclyde University, Glasgow G1 1XQ, UK.
  • Jit M; Immunization, Vaccines and Biologicals Department, WHO, 1211 Geneva, Switzerland.
Vaccines (Basel) ; 12(4)2024 Apr 18.
Article en En | MEDLINE | ID: mdl-38675817
ABSTRACT
For vaccine development and adoption decisions, the 'Full Value of Vaccine Assessment' (FVVA) framework has been proposed by the WHO to expand the range of evidence available to support the prioritization of candidate vaccines for investment and eventual uptake by low- and middle-income countries. Recent applications of the FVVA framework have already shown benefits. Building on the success of these applications, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention. These opportunities include the following (1) FVVA producers should aim to create evidence that explicitly meets the needs of multiple key FVVA consumers, (2) the WHO and other key stakeholders should develop standardized methodologies for FVVAs, as well as guidance for how different stakeholders can explicitly reflect their values within the FVVA framework, and (3) the WHO should convene experts to further develop and prioritize the research agenda for outcomes and benefits relevant to the FVVA and elucidate methodological approaches and opportunities for standardization not only for less well-established benefits, but also for any relevant research gaps. We encourage FVVA stakeholders to engage with these opportunities.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido